🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementMuscle cramps on semaglutide — what worked for you?

Muscle cramps on semaglutide — what worked for you?

RegAffairsDC Fri, Jan 16, 2026 at 8:32 AM 9 replies 1,007 viewsPage 1 of 2
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
Jan 16, 2026 at 8:32 AM#1

Started at 0.25mg with a fairly bad first week, held each step the full four weeks, and I am now at 1mg with no side effects worth naming.

For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.

What I am after is what the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss.

Practical detail welcome, however dull — the duller the better.

38 8amy_econ_NJ, bbq_ray_KC, oliver_london and 35 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Jan 16, 2026 at 9:01 AM#2

Short answer first, then the reasoning. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

37 7VanRx_Mike, steve_okc, dave_SLC and 34 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Jan 16, 2026 at 9:30 AM#3
kate.chem said:
The mechanism that matters here is not stomach emptying, it is central.

That is correct as far as it goes, and here is where it stops going. Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

36 6NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 33 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
nick_SD_fit
Member
278
1,234
Sep 2024
San Diego, CA
Jan 16, 2026 at 9:59 AM#4
RegAffairsDC said:
Started at 0.25mg with a fairly bad first week, held each step the full four weeks, and I am now at 1mg with no side effects worth naming.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

35 5PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 32 others
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Jan 16, 2026 at 12:37 PM#5

From the other side of the consultation, briefly.

RegAffairsDC said:
...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

Last edited: Jan 16, 2026 at 2:37 PM
34 4pat_auckland, Dr.GastroMayo, JakeBK_lifts and 31 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register